- Home
- ATOS vs INFU Comparison
ATOS vs INFU Comparison
Compare ATOS & INFU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATOS
- INFU
- Stock Information
- Founded
- ATOS 2009
- INFU 2005
- Country
- ATOS United States
- INFU United States
- Employees
- ATOS N/A
- INFU N/A
- Industry
- ATOS Biotechnology: Pharmaceutical Preparations
- INFU Medical/Dental Instruments
- Sector
- ATOS Health Care
- INFU Health Care
- Exchange
- ATOS Nasdaq
- INFU Nasdaq
- Market Cap
- ATOS 112.5M
- INFU 104.4M
- IPO Year
- ATOS 2012
- INFU N/A
- Fundamental
- Price
- ATOS $0.86
- INFU $6.10
- Analyst Decision
- ATOS Strong Buy
- INFU
- Analyst Count
- ATOS 4
- INFU 0
- Target Price
- ATOS $6.17
- INFU N/A
- AVG Volume (30 Days)
- ATOS 668.8K
- INFU 155.4K
- Earning Date
- ATOS 05-13-2025
- INFU 08-07-2025
- Dividend Yield
- ATOS N/A
- INFU N/A
- EPS Growth
- ATOS N/A
- INFU 3654.89
- EPS
- ATOS N/A
- INFU 0.15
- Revenue
- ATOS N/A
- INFU $137,582,000.00
- Revenue This Year
- ATOS N/A
- INFU $11.08
- Revenue Next Year
- ATOS N/A
- INFU $8.02
- P/E Ratio
- ATOS N/A
- INFU $40.78
- Revenue Growth
- ATOS N/A
- INFU 7.98
- 52 Week Low
- ATOS $0.55
- INFU $4.61
- 52 Week High
- ATOS $1.66
- INFU $9.97
- Technical
- Relative Strength Index (RSI)
- ATOS 51.39
- INFU 59.28
- Support Level
- ATOS $0.84
- INFU $5.89
- Resistance Level
- ATOS $0.93
- INFU $6.19
- Average True Range (ATR)
- ATOS 0.06
- INFU 0.27
- MACD
- ATOS -0.00
- INFU 0.02
- Stochastic Oscillator
- ATOS 66.40
- INFU 91.89
About ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.
About INFU InfuSystems Holdings Inc.
InfuSystems Holdings Inc is a health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers. INFU services are provided under a two-reportable segment. The first is Patient Services, providing the last-mile solution for clinic-to-home healthcare where the continuing treatment involves complex durable medical equipment and services. The Patient segment is comprised of Oncology, Pain Management and Wound Therapy businesses. The second, Device Solutions, supports the Patient Services platform and leverages service orientation to win incremental business from its direct payer clients. The Device segment is comprised of direct payer rentals, pump and consumable sales, and biomedical services and repair. Majority from Patient.